CD55/DAF Matched ELISA Antibody Pair Set,Human

For the orders from outside of China: MOQ 15 plates, lead time: 2 weeks.
1/1
Price:
Size:
Number:

CD55/DAF Matched ELISA Antibody Pair Set,Human 产品信息

产品名称
CD55/DAF Matched ELISA Antibody Pair Set,Human
检测原理
Solid Phase Sandwich ELISA
特异性
Quantitative determination of Human CD55/DAF
线性范围
23.44-1500 pg/mL
ELISA 抗体对套装(非即用型)组分
1. Capture Antibody 1.0 mg/mL of rabbit anti-CD55 monoclonal antibody. Dilute to a working concentration of 2 μg/mL in CBS before coating. (Catalog: # 10101-R028)
2. Detection Antibody 0.4 mg/mL mouse anti-CD55 monoclonal antibody conjugated to horseradish-peroxidase (HRP). Dilute to working concentration of 0.2 μg/mL in detection antibody dilution buffer before use. (Catalog: # 10101-MM03)
3. Standard Each vial contains 30 ng of recombinant CD55. Reconstitute with 1 mL detection antibody dilution buffer. After reconstitution, store at -20℃ to -80℃ in a manual defrost freezer. A seven-point standard curve usi ng 2-fold serial dilutions in sample dilution buffer, and a high standard of 1.5 ng/mL is recommended
产品概述
This CD55/DAF Matched ELISA Antibody Pair Set,Human is a solid phase sandwich ELISA for quantitative determination of Human CD55/DAF . It contains Human CD55/DAF capture antibody, Human CD55/DAF detector antibody (HRP) and a highly purified HEK293-expressed recombinant Human CD55/DAF protein. This Pair Set is at affordable price for researchers.
运输方式
This Matched ELISA Antibody Pair Set is shipped at ambient temperature.
储存条件
Capture Antibody: Aliquot and store at -20℃ to -80℃ for up to 6 months from date of receipt. Avoid repeated freeze-thaw cycles.
Detection Antibody: Protect it from prolonged exposure to light. Aliquot and store at -20℃ to -80℃ and for up to 6 months from date of receipt. Avoid repeated freeze-thaw cycles.
Standard: Store lyophilized standard at -20℃ to -80℃ for up to 6 months from date of receipt. Aliquot and store the reconstituted Standard at -80℃ for up to 1 month. Avoid repeated freeze-thaw cycles.

CD55/DAF Matched ELISA Antibody Pair Set,Human 图片

CD55/DAF Matched ELISA Antibody Pair Set,Human: 别称

CR Matched ELISA Antibody Pair Set, Human; CROM Matched ELISA Antibody Pair Set, Human; DAF Matched ELISA Antibody Pair Set, Human; TC Matched ELISA Antibody Pair Set, Human

CD55/DAF 背景信息

CD55, also well known as decay-accelerating factor (DAF), is a member of the RCA (regulators of complement activation) family characterized by four to 30 SCRs (short consensus repeats) in their plasma-exposed regions. It is a major regulator of the alternative and classical pathways of complement activation and is expressed on all serum-exposed cells. CD55 is physiologically acting as an inhibitor of the complement system, but is also broadly expressed in malignant tumours. DAF seems to exert different functions beyond its immunological role such as promotion of tumorigenesis, decrease of complement mediated tumor cell lysis, autocrine loops for cell rescue and evasion of apoptosis, neoangiogenesis, invasiveness, cell motility. It is commonly hijacked by invading pathogens, including many enteroviruses and uropathogenic Escherichia coli, to promote cellular attachment prior to infection. This 70-75 kDa glycoprotein CD55 containing four SCR modules is involved in the regulation of the complement cascade. It inhibits complement activation by suppressing the function of C3/C5 convertases, thereby limiting local generation or deposition of C3a/C5a and membrane attack complex (MAC or C5b-9) production. DAF has been identified as a ligand for an activation-associated, seven-transmembrane lymphocyte receptor, CD97, which is a receptor mediating attachment and infection of several viruses and bacteria. In addition, it has been shown that DAF regulates the interplay between complement and T cell immunity in vivo, and thus may be implicated in immune and tumor biology.
全称
CD55 molecule, decay accelerating factor for complement (Cromer blood group)
Related Pathways
  • Complement Activation Pathways
    Complement Activation Pathways
参考文献
  • Lea S. (2002) Interactions of CD55 with non-complement ligands. Biochem Soc Trans. 30(Pt 6): 1014-9.
  • Mikesch JH, et al. (2006) The expression and action of decay-accelerating factor (CD55) in human malignancies and cancer therapy. Cell Oncol. 28(5-6): 223-32.
  • Wang Y, et al. (2010) Decay accelerating factor (CD55) protects neuronal cells from chemical hypoxia-induced injury. J Neuroinflammation. 7:24.
添加购物车成功! 添加购物车失败!请再次尝试 正在更新购物车,请稍后 U.S.A.